NewEdge Wealth LLC bought a new position in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 245,670 shares of the company's stock, valued at approximately $3,656,000. NewEdge Wealth LLC owned about 0.16% of Biohaven at the end of the most recent quarter.
A number of other hedge funds have also added to or reduced their stakes in BHVN. PNC Financial Services Group Inc. lifted its position in Biohaven by 113.7% during the 3rd quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company's stock worth $36,000 after buying an additional 1,268 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Biohaven by 178.4% during the 4th quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company's stock worth $46,000 after buying an additional 2,583 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Biohaven by 55.4% in the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company's stock valued at $46,000 after acquiring an additional 1,450 shares in the last quarter. Arax Advisory Partners grew its holdings in shares of Biohaven by 943.3% in the 4th quarter. Arax Advisory Partners now owns 4,914 shares of the company's stock valued at $55,000 after acquiring an additional 4,443 shares in the last quarter. Finally, Focus Partners Wealth acquired a new stake in shares of Biohaven in the third quarter valued at about $87,000. Institutional investors own 88.78% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts recently commented on the company. HC Wainwright reissued a "neutral" rating and set a $10.00 price target on shares of Biohaven in a research report on Tuesday, May 26th. Needham & Company LLC set a $11.00 price target on Biohaven in a research report on Monday, June 29th. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Biohaven in a research note on Friday, June 26th. Wall Street Zen raised Biohaven from a "strong sell" rating to a "sell" rating in a report on Saturday, June 27th. Finally, Raymond James Financial reissued a "strong-buy" rating on shares of Biohaven in a research note on Wednesday, May 27th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $21.75.
Read Our Latest Report on Biohaven
Biohaven Price Performance
NYSE:BHVN opened at $13.57 on Friday. The company has a quick ratio of 4.73, a current ratio of 4.73 and a debt-to-equity ratio of 21.23. The stock's 50 day moving average price is $14.54 and its two-hundred day moving average price is $11.73. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -2.92 and a beta of 1.26. Biohaven Ltd. has a 12-month low of $7.48 and a 12-month high of $18.57.
Biohaven (NYSE:BHVN - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, analysts anticipate that Biohaven Ltd. will post -3.11 earnings per share for the current year.
About Biohaven
(
Free Report)
Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.
The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
